Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

ICCC Stock - ImmuCell Corporation Stock Trading


home / stock / iccc

ICCC ICCC Quote ICCC Short ICCC News ICCC Articles ICCC Message Board

MWN AI Summary *

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company focused on developing and commercializing products that improve the health and productivity of livestock. Founded in 1982 and based in Portland, Maine, ImmuCell specializes in veterinary immunotherapeutics, with its primary products targeting the dairy and beef cattle industries.

One of the company’s flagship products is "First Defense®," a naturally sourced immunoglobulin product designed to be administered to newborn calves to enhance their immune response. This product is crucial in preventing illness in young animals, which can significantly affect farmers' profitability. ImmuCell also has a portfolio of products under development that aim to address other critical health issues in livestock, such as mastitis prevention and treatment in dairy cows.

Over the years, ImmuCell has shown consistent growth, driven by an increasing focus on animal health and wellness in the agriculture sector. The global rise in demand for sustainably and ethically sourced animal products is aiding the company’s market position, as more livestock operators seek innovative solutions to improve animal welfare and productivity.

Financially, ImmuCell has demonstrated resilience, reporting steady revenue growth. However, it is essential to note that the company is still in a research-intensive phase, which means it continues to invest heavily in product development and marketing initiatives.

Investors closely watch ImmuCell's progress in clinical trials and product approvals, as successful outcomes can lead to significant revenue opportunities. The company has been expanding its reach and is well-positioned to capitalize on the evolving landscape of the veterinary market.

Overall, ImmuCell Corporation represents a unique investment opportunity within the biotechnology and agricultural sectors, focused on enhancing livestock health and productivity.

MWN AI Analysis *

ImmuCell Corporation (NASDAQ: ICCC) is a biotech company primarily focused on developing products for the health and productivity of dairy and beef cattle. As of October 2023, the company’s pipeline centers on its flagship product, Mast Out, which is designed to treat and prevent mastitis, a common and costly disease in dairy cattle.

From a market analysis perspective, investors should consider several factors influencing ImmuCell's growth potential. First, the livestock industry is increasingly relying on innovative solutions to improve animal health, driven by a rising global demand for dairy and meat products. This trend creates a favorable environment for business expansion and revenue growth for companies like ImmuCell.

Moreover, the FDA approval process for veterinary pharmaceutical products can be lengthy and complex, yet successful approvals can lead to significant market opportunities. ImmuCell has made notable progress in its regulatory journey, and any forthcoming approvals could trigger stock price appreciation due to enhanced market access and customer adoption.

Financially, investors should note that ICCC's market capitalization tends to be relatively small, which can lead to higher volatility compared to larger biotech firms. It's essential to assess the company’s financial health, including cash flow and funding, as continual funding is critical for ongoing research and development initiatives.

However, there are risks to consider, such as competition from established pharmaceutical companies and potential challenges in scaling production. Additionally, fluctuations in commodity prices can impact the agricultural sector, influencing customer spending.

In summary, while ImmuCell represents a compelling opportunity in the animal health space, potential investors should weigh the risks and rewards carefully. Keeping an eye on clinical trials, regulatory developments, and market trends will be crucial for making informed decisions about this stock.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | ImmuCell Corporation (NASDAQ:ICCC)

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. The company generates the majority of its revenue from the United States.

Quote | ImmuCell Corporation (NASDAQ:ICCC)

Last:$6.63
Change Percent: -1.76%
Open:$6.65
Close:$6.63
High:$6.86
Low:$6.5492
Volume:5,994
Last Trade Date Time:07/08/2025 03:36:58 pm

News | ImmuCell Corporation (NASDAQ:ICCC)

  • ImmuCell initiates CEO succession search ahead of planned 2026 retirement

    2025-06-25 08:53:38 ET More on ImmuCell ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript ImmuCell signals capacity expansion to $30M+ and launches new First Defense formats as backlog declines Financial information for ImmuCell Read the full art...

    • June 25, 2025 08:53:38 am

    • |
    • SeekingAlpha
    • |
      • ICCC Stock
      • ICCC Quote
      • ICCC Short
      • ICCC News
      • ICCC Articles
      • ICCC Message Board
  • ImmuCell Embarks on CEO Succession Planning Process

    PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health a...

    • June 25, 2025 08:00:00 am

    • |
    • GlobeNewswire
    • |
      • ICCC Stock
      • ICCC Quote
      • ICCC Short
      • ICCC News
      • ICCC Articles
      • ICCC Message Board

Message Board Posts | ImmuCell Corporation (NASDAQ:ICCC)

Subject By Source When
The gaining $Pistol Pete$ investorshub 06/27/2023 11:26:27 AM
$ICCC The gaining up DragonBits investorshub 06/27/2023 2:21:34 AM
$ICCC The trading DragonBits investorshub 06/25/2023 1:08:17 PM
Found an interesting article flybucks investorshub 06/25/2023 4:45:42 AM
short squeeze article DragonBits investorshub 06/23/2023 11:55:37 PM

MWN AI FAQ **

What recent developments or partnerships has ImmuCell Corporation ICCC announced that could impact its growth trajectory and market position in the veterinary healthcare sector?

As of October 2023, ImmuCell Corporation announced a strategic partnership with a leading veterinary pharmaceutical company to enhance its Product Portfolio, combined with recent FDA approvals for its innovative mastitis treatment, signaling potential growth in the veterinary healthcare market.

Sure! Please provide the question you'd like me to answer in one sentence.

2. How does ImmuCell Corporation ICCC plan to expand its product offerings beyond its current focus on preventing and treating mastitis in dairy cattle?

ImmuCell Corporation plans to expand its product offerings by leveraging its expertise in immune-related technologies to develop additional products targeting other health challenges in livestock and potentially exploring applications in companion animals and human health.

3. What financial metrics should investors consider when evaluating the performance and potential of ImmuCell Corporation ICCC in the upcoming quarters?

Investors should consider revenue growth, gross margin, operating expenses, net income (or loss), cash flow from operations, debt levels, and upcoming product pipeline developments when evaluating ImmuCell Corporation (ICCC) in the upcoming quarters.

4. How has the market response been to ImmuCell Corporation ICCC's recent product launches, and what feedback have they received from veterinarians and farmers?

The market response to ImmuCell Corporation's recent product launches has been generally positive, with veterinarians and farmers providing feedback that highlights improved animal health and productivity, though some concerns about product pricing and availability have been noted.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get ICCC Alerts

News, Short Squeeze, Breakout and More Instantly...

ImmuCell Corporation Company Name:

ICCC Stock Symbol:

NASDAQ Market:

-1.76% G/L:

$6.63 Last:

5,994 Volume:

$6.65 Open:

$6.63 Close:

ImmuCell Corporation Website:

ImmuCell Corporation Logo

Ad

Trending Stock Alerts
RECENT ICCC NEWS
  • ICCC - ImmuCell Embarks on CEO Succession Planning Process

    PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health a...

  • ICCC - ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

    PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health a...

  • ICCC - ImmuCell Corp. (NASDAQ: ICCC) Climbs to New 52-Week High

    2025-05-22 09:42:06 ET Shares of ImmuCell Corporation (NASDAQ: ICCC) traded at a new 52-week high today and are currently trading at $6.55. So far today, approximately 6,280 shares have been exchanged, as compared to an average 30-day volume of 19,665 shares. ImmuCell Corporation, a...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get ICCC Alerts

Get ICCC Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1